Axel Bolte - Net Worth and Insider Trading
Axel Bolte Net Worth
The estimated net worth of Axel Bolte is at least $2 Million dollars as of 2024-12-27. Axel Bolte is the Director of PTC Therapeutics Inc and owns about 20,000 shares of PTC Therapeutics Inc (PTCT) stock worth over $914,600. Axel Bolte is the CEO of Inozyme Pharma Inc and owns about 258,575 shares of Inozyme Pharma Inc (INZY) stock worth over $770,554. Axel Bolte is also the Director of IVERIC bio Inc and owns about 0 shares of IVERIC bio Inc (ISEE) stock worth over $0. Details can be seen in Axel Bolte's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Axel Bolte has not made any transactions after 2022-04-19 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Axel Bolte
Axel Bolte Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Axel Bolte owns 5 companies in total, including Inozyme Pharma Inc (INZY) , IVERIC bio Inc (ISEE) , and Allena Pharmaceuticals Inc (ALNAQ) among others .
Click here to see the complete history of Axel Bolte’s form 4 insider trades.
Insider Ownership Summary of Axel Bolte
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| INZY | Inozyme Pharma Inc | 2022-04-19 | director & 10 percent owner & See Remarks |
| ISEE | IVERIC bio Inc | 2016-12-30 | director |
| ALNAQ | Allena Pharmaceuticals Inc | 2017-11-01 | director |
 | | 2016-12-30 | director |
| | 2013-06-25 | director |
Axel Bolte Latest Holdings Summary
Axel Bolte currently owns a total of 3 stocks. Among these stocks, Axel Bolte owns 20,000 shares of PTC Therapeutics Inc (PTCT) as of June 25, 2013, with a value of $914,600 and a weighting of 54.27%. Axel Bolte owns 258,575 shares of Inozyme Pharma Inc (INZY) as of April 19, 2022, with a value of $770,554 and a weighting of 45.73%. Axel Bolte also owns 0 shares of IVERIC bio Inc (ISEE) as of December 30, 2016, with a value of $0 and a weighting of 0%.
Latest Holdings of Axel Bolte
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| PTCT | PTC Therapeutics Inc | 2013-06-25 | 20,000 | 45.73 | 914,600 |
| INZY | Inozyme Pharma Inc | 2022-04-19 | 258,575 | 2.98 | 770,554 |
| ISEE | IVERIC bio Inc | 2016-12-30 | 0 | 39.95 | 0 |
Holding Weightings of Axel Bolte
Axel Bolte Form 4 Trading Tracker
According to the SEC Form 4 filings, Axel Bolte has made a total of 0 transactions in PTC Therapeutics Inc (PTCT) over the past 5 years. The most-recent trade in PTC Therapeutics Inc is the acquisition of 20,000 shares on June 25, 2013, which cost Axel Bolte around $300,000.
According to the SEC Form 4 filings, Axel Bolte has made a total of 1 transactions in Inozyme Pharma Inc (INZY) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Inozyme Pharma Inc is the acquisition of 67,750 shares on April 19, 2022, which cost Axel Bolte around $249,998.
According to the SEC Form 4 filings, Axel Bolte has made a total of 0 transactions in IVERIC bio Inc (ISEE) over the past 5 years. The most-recent trade in IVERIC bio Inc is the sale of 6,000 shares on December 30, 2016, which brought Axel Bolte around $28,980.
Insider Trading History of Axel Bolte
- 1
Axel Bolte Trading Performance
GuruFocus tracks the stock performance after each of Axel Bolte's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Axel Bolte is 11.24%. GuruFocus also compares Axel Bolte's trading performance to market benchmark return within the same time period. The performance of stocks bought by Axel Bolte within 3 months outperforms 3 times out of 4 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Axel Bolte's insider trading performs compared to the benchmark.
Performance of Axel Bolte
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -6.84 | | | | | |
| Relative Return to S&P 500(%) | -5.34 | | | | | |
Axel Bolte Ownership Network
Axel Bolte Owned Company Details
What does Inozyme Pharma Inc do?
Who are the key executives at Inozyme Pharma Inc?
Axel Bolte is the director & 10 percent owner & See Remarks of Inozyme Pharma Inc. Other key executives at Inozyme Pharma Inc include director & 10 percent owner Robert Lorne Hopfner , COO Matthew Winton , and See Remarks Henric Bjorn Bjarke .
Inozyme Pharma Inc (INZY) Insider Trades Summary
Over the past 18 months, Axel Bolte made no insider transaction in Inozyme Pharma Inc (INZY). Other recent insider transactions involving Inozyme Pharma Inc (INZY) include a net purchase of 833,333 shares made by Pivotal Bioventure Partners Fund I G.p., L.p. , a net purchase of 833,333 shares made by Robert Lorne Hopfner , and a net sale of 7,523 shares made by Douglas A Treco .
In summary, during the past 3 months, insiders sold 0 shares of Inozyme Pharma Inc (INZY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,523 shares of Inozyme Pharma Inc (INZY) were sold and 1,666,666 shares were bought by its insiders, resulting in a net purchase of 1,659,143 shares.
Inozyme Pharma Inc (INZY)'s detailed insider trading history can be found in Insider Trading Tracker table.
Inozyme Pharma Inc Insider Transactions
Axel Bolte Mailing Address
Above is the net worth, insider trading, and ownership report for Axel Bolte. You might contact Axel Bolte via mailing address: Ptc Therapeutics, Inc., 100 Corporate Court, South Plainfield Nj 07080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
